[18F]-Alfatide PET 靶向整合素 αvβ3 无创定量肝纤维化
研究在小鼠 CCl4 与 BDL 纤维化模型中,用 [18F]-Alfatide PET 联合 CT、病理、免疫荧光、免疫印迹和基因分析,评估肝脏整合素 αvβ3 水平与纤维化进展。结果显示纤维化肝摄取与滞留增强,示踪剂特异性结合主要表达于活化肝星状细胞的整合素 αvβ3,人纤维化肝组织分析支持动物结果。
要点
- 纤维化小鼠肝对 [18F]-Alfatide 摄取与滞留较对照增强,并与整合素 αvβ3 表达相关。
- 示踪剂主要特异性结合活化肝星状细胞上的整合素 αvβ3。
- 以肝 AUC/血 AUC(30 分钟)作为 PET 指数可定量纤维化进展。
核心结论
- PET 联合 [18F]-Alfatide 靶向肝整合素 αvβ3,可能成为无创监测肝纤维化进展的方法。
研究设计与样本
- 研究在 CCl4 与胆管结扎(BDL)小鼠纤维化模型中行 [18F]-Alfatide PET、平扫 CT、组织病理、免疫荧光、免疫印迹和基因分析。
- 以 30 分钟内肝 AUC 除以血 AUC 作为整合素 αvβ3-PET 指数定量纤维化进展。
- 对纤维化与肝硬化患者冷冻肝组织行离体分析以验证动物发现。
主要发现
- 纤维化小鼠肝较对照肝显示 [18F]-Alfatide 摄取与滞留增强。
- 示踪剂被证实特异性结合整合素 αvβ3,后者主要表达于活化肝星状细胞。
- 放射自显影与组织病理确认了 PET 成像结果。
- CCl4 与 BDL 模型中整合素 αvβ3 及其信号复合物的 mRNA 和蛋白水平高于对照。
- 人纤维化肝切片分析结果支持动物发现。
临床怎么用
- [18F]-Alfatide PET 有望作为无创影像生物标志物追踪肝纤维化进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The vitronectin receptor integrin αvβ3 drives fibrogenic activation of hepatic stellate cells (HSCs). Molecular imaging targeting the integrin αvβ3 could provide a non-invasive method for evaluating the expression and the function of the integrin αvβ3 on activated HSCs (aHSCs) in the injured liver. In this study, we sought to compare differences in the uptake of [18F]-Alfatide between normal and injured liver to evaluate its utility for assessment of hepatic fibrogenesis. METHODS: PET with [18F]-Alfatide, non-enhanced CT, histopathology, immunofluorescence staining, immunoblotting and gene analysis were performed to evaluate and quantify hepatic integrin αvβ3 levels and liver fibrosis progression in mouse models of fibrosis (carbon tetrachloride [CCl4] and bile duct ligation [BDL]). The liver AUC divided by the blood AUC over 30 min was used as an integrin αvβ3-PET index to quantify fibrosis progression. Ex vivo analysis of frozen liver tissue from patients with fibrosis and cirrhosis verified the animal findings. RESULTS: Fibrotic mouse livers showed enhanced [18F]-Alfatide uptake and retention compared to control livers. The radiotracer was demonstrated to bind specifically with integrin αvβ3, which is mainly expressed on aHSCs. Autoradiography and histopathology confirmed the PET imaging results. Further, the mRNA and protein level of integrin αvβ3 and its signaling complex were higher in CCl4 and BDL models than controls. The results obtained from analyses on human fibrotic liver sections supported the animal findings. CONCLUSIONS: Imaging hepatic integrin αvβ3 with PET and [18F]-Alfatide offers a potential non-invasive method for monitoring the progression of liver fibrosis. LAY SUMMARY: Integrin αvβ3 expression on activated hepatic stellate cells (aHSCs) is associated with HSC proliferation during hepatic fibrogenesis. Herein, we show that a radioactive tracer, [18F]-Alfatide, binds to integrin αvβ3 with high affinity and specificity. [18F]-Alfatide could thus be used as a non-invasive imaging biomarker to track hepatic fibrosis progression.
引用
- Shao T, Chen Z, Belov V, et al. [18F]-Alfatide PET imaging of integrin αvβ3 for the non-invasive quantification of liver fibrosis. J Hepatol. 2020. PMID: 32145257. doi:10.1016/j.jhep.2020.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。